prikaz prve stranice dokumenta Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
  Download
PDF 1.06 MB
Scientific paper - Original scientific paper
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
Inflammatory Bowel Diseases, 30 (2024), 5; 768-779. https://doi.org/10.1093/ibd/izad135
(TFB Study Group) Resál, Tamás; Bacsur, Péter; Keresztes, Csilla; Bálint, Anita; Bor, Renáta; Fábián, Anna; Farkas, Bernadett; Katsanos, Kostas; Michalopoylos, George; Ribaldone, Davide Giuseppe; Attauabi, Mohamed; Zhao, Mirabella; Barak, Hadar Amir; Yanai, Henit; Bezzio, Cristina; Rispo, Antonio; Castiglione, Fabiana; Bar-Gil Shitrit, Ariella; Pugliese, Daniela; Armuzzi, Alessandro; Savarino, Edoardo Vincenzo; Kolar, Martin; Lukáš, Milan; Chashkova, Elena; Filip, Rafał; Rozieres, Aurore; Nancey, Stéphane; Krznarić, Željko; Schäfer, Eszter; Szamosi, Tamás; Sarlós, Patrícia; Franko, Matej; Drobne, David; Knyazev, Oleg V; Kagramanova, Anna V; Limdi, Jimmy; Wetwittayakhlang, Panu; Lakatos, Peter L; Maharshak, Nitsan; Bannon, Lian; Nyári, Tibor; Szepes, Zoltán; Farkas, Klaudia; Molnár, Tamás More authors...

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Resál, T., Bacsur, P., Keresztes, C., Bálint, A., Bor, R., Fábián, A. ... Molnár, T. (2024). Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Inflammatory Bowel Diseases, 30. (5), 768-779. doi: 10.1093/ibd/izad135

Resál, Tamás, et al. "Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study." Inflammatory Bowel Diseases, vol. 30, no. 5, 2024, pp. 768-779. https://doi.org/10.1093/ibd/izad135

Resál, Tamás, Péter Bacsur, Csilla Keresztes, Anita Bálint, Renáta Bor, Anna Fábián, Bernadett Farkas, et al. "Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study." Inflammatory Bowel Diseases 30, no. 5 (2024): 768-779. https://doi.org/10.1093/ibd/izad135

Resál, T., et al. (2024) 'Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study', Inflammatory Bowel Diseases, 30(5), pp. 768-779. doi: 10.1093/ibd/izad135

Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, and sur.. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Inflammatory Bowel Diseases [Internet]. 2024 May 01 [cited 2024 November 27];30(5):768-779. doi: 10.1093/ibd/izad135

T. Resál, et al., "Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study", Inflammatory Bowel Diseases, vol. 30, no. 5, pp. 768-779, May 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:675377. [Accessed: 27 November 2024]

Metadata
Title (english)Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study
AuthorTamás Resál
AuthorPéter Bacsur
AuthorCsilla Keresztes
AuthorAnita Bálint
AuthorRenáta Bor
AuthorAnna Fábián
AuthorBernadett Farkas
AuthorKostas Katsanos
AuthorGeorge Michalopoylos
AuthorDavide Giuseppe Ribaldone
AuthorMohamed Attauabi
AuthorMirabella Zhao
AuthorHadar Amir Barak
AuthorHenit Yanai
AuthorCristina Bezzio
AuthorAntonio Rispo
AuthorFabiana Castiglione
AuthorAriella Bar-Gil Shitrit
AuthorDaniela Pugliese
AuthorAlessandro Armuzzi
AuthorEdoardo Vincenzo Savarino
AuthorMartin Kolar
AuthorMilan Lukáš
AuthorElena Chashkova
AuthorRafał Filip
AuthorAurore Rozieres
AuthorStéphane Nancey
AuthorŽeljko Krznarić
MBZ: 75865
AuthorEszter Schäfer
AuthorTamás Szamosi
AuthorPatrícia Sarlós
AuthorMatej Franko
AuthorDavid Drobne
AuthorOleg V Knyazev
AuthorAnna V Kagramanova
AuthorJimmy Limdi
AuthorPanu Wetwittayakhlang
AuthorPeter L Lakatos
AuthorNitsan Maharshak
AuthorLian Bannon
AuthorTibor Nyári
AuthorZoltán Szepes
AuthorKlaudia Farkas
AuthorTamás Molnár
CollaborationTFB Study Group
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background and aims: Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC. Methods: This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022. Indications were categorized as ASUC and chronic activity (CA). Baseline demographic and clinical data were obtained. Steroid-free remission (SFR), colectomy, and safety data were analyzed. Results: A total of 391 UC patients (median age 38 [interquartile range, 28-47] years; follow-up period 26 [interquartile range, 14-52] weeks) were included. A total of 27.1% received TFB in ASUC. SFR rates were 23.7% (ASUC: 26.0%, CA: 22.8%) at week 12 and 41.1% (ASUC: 34.2%, CA: 43.5%) at week 52. The baseline partial Mayo score (odds ratio [OR], 0.850; P = .006) was negatively associated with week 12 SFR, while biologic-naïve patients (OR, 2.078; P = .04) more likely achieved week 52 SFR. The colectomy rate at week 52 was higher in ASUC group (17.6% vs 5.7%; P < .001) and decreased with age (OR, 0.94; P = .013). A total of 67 adverse events were reported, and 17.9% resulted in cessation of TFB. One case of thromboembolic event was reported. Conclusions: TFB is effective in both studied indications. TFB treatment resulted in high rates of SFR in the short and long terms. Higher baseline disease activity and previous biological therapies decreased efficacy. No new adverse event signals were found.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleInflammatory Bowel Diseases
Numberingvol. 30, no. 5, pp. 768-779
p-ISSN1078-0998
e-ISSN1536-4844
DOIhttps://doi.org/10.1093/ibd/izad135
URN:NBNurn:nbn:hr:105:675377
Publication2024-05-01
Document URLhttps://academic.oup.com/ibdjournal/article/30/5/768/7237867
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2024-09-03 10:51:07